Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telaprevir + peginterferon alfa-2a
- Development stage
- Discontinued
- Lead developer
- Vertex
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
**Telaprevir + peginterferon alfa-2a** is a combination regimen used in the treatment of chronic hepatitis C virus (HCV) infection, particularly in patients with HCV genotype 1. Telaprevir is a direct-acting antiviral agent classified as a NS3/4A serine protease inhibitor, which blocks a key viral enzyme necessary for Hepatitis C viral replication. Peginterferon alfa-2a is a modified recombinant human interferon that stimulates antiviral immune responses by binding to type 1 interferon receptors and activating the JAK/STAT pathway. When used together (often with ribavirin), the combination enhances viral clearance and improves sustained viral response rates.
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on telaprevir + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telaprevir + peginterferon alfa-2a.